Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $33.1 million versus the consensus estimate of $35.86 million.

GUIDANCE:

Karyopharm Therapeutics sees Q2 2024 revenue of $140-160 million, versus the consensus of $146.5 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.